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A double-blind, randomized, comparative study of 
the use of a combination of uridine triphosphate 
trisodium, cytidine monophosphate disodium, and 
hydroxocobalamin, versus isolated treatment with 
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Context: This paper reports on the results of treatment of compressive neuralgia using a 
combination of nucleotides (uridine triphosphate trisodium [UTP] and cytidine monophosphate 
disodium [CMP]) and vitamin B
12
.
Objectives:  To assess the safety and efficacy of the combination of nucleotides (UTP and 
CMP) and vitamin B
12
 in patients presenting with neuralgia arising from neural compression 
associated with degenerative orthopedic alterations and trauma, and to compare these effects 
with isolated administration of vitamin B
12
.  
Methods: A randomized, double-blind, controlled trial, consisting of a 30-day oral treatment 
period: Group A (n=200) receiving nucleotides + vitamin B
12,
 and Group B (n=200) receiving 
vitamin B
12
 alone. The primary study endpoint was the percentage of subjects presenting pain 
visual analog scale (VAS) scores ≤20 at end of study treatment period. Secondary study endpoints 
included the percentage of subjects presenting improvement ≥5 points on the patient functionality 
questionnaire (PFQ); percentage of subjects presenting pain reduction (reduction in VAS scores 
at study end in relation to pretreatment); and number of subjects presenting adverse events. 
Results: The results of this study showed a more expressive improvement in efficacy evaluations 
among subjects treated with the combination of nucleotides + vitamin B
12
, with a statistically 
significant superiority of the combination in pain reduction (evidenced by VAS scores). There 
were adverse events in both treatment groups, but these were transitory and no severe adverse 
event was recorded during the study period. Safety parameters were maintained throughout the 
study in both treatment groups.
Conclusion: The combination of uridine, cytidine, and vitamin B
12
 was safe and effective 
in the treatment of neuralgias arising from neural compression associated with degenerative 
orthopedic alterations and trauma.
Keywords: uridine triphosphate trisodium, cytidine monophosphate disodium, hydroxocobala-
min, compressive neuralgia
Introduction
Uridine and cytidine are substances belonging to the pyrimidine nucleotide family, 
which in turn comprises one of four main classes of biological molecules (along 
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with carbohydrates, lipids, and proteins) that play several 
fundamental roles in cellular metabolism. Aside from being 
components of DNA and participating in genome transcrip-
tion and translation, functions of these nucleotides include 
energy transfer for chemical bonding, intracellular signaling, 




 is essential in the human body for growth 
and maintenance of a variety of processes, including cell 
reproduction and synthesis of myelin and nucleoproteins, 
and must be supplied from an exogenous source.2 Adequate 
vitamin B
12
 levels in the body depend on adequate ingestion 
and absorption (requiring an acid-pepsin complex in the 
stomach that releases cobalamin from its binding proteins, 
pancreatic proteins that release cobalamin from the R factor 
bond, secretion of intrinsic factor by gastric parietal cells 
in order to bind cobalamin, and the presence of cobalamin 
and intrinsic factor receptors in the ileum.3,4 Vitamin B
12
 
is important to nerve metabolism via the remethylation 
of homocysteine to methionine for de novo synthesis of 
s-Adenosyl methionine.5  Vitamin B
12
 deficiency can be 
caused by numerous factors, usually some combination of 
inadequate ingestion and absorption.6 Deficiency can lead 
to megaloblastic anemia and neurological alterations, the 
latter likely linked to the absence of s-Adenosyl methionine 
formation.7, 8 
This trial assessed treatment outcomes following 
administration of a combination of uridine triphosphate 
trisodium (UTP), cytidine monophosphate disodium 
(CMP), and vitamin B
12
 in the treatment of patients with 
compressive neuralgias. There is a body of clinical and 
preclinical evidence in the literature, supporting use of 
CMP and UTP in neuropathic pain, with potential symp-
tomatic benefits.9-22  
Several preclinical studies of peripheral neuropathies 
of varying etiologies have indicated beneficial effects 
of UTP and CMP administration in situations such as 
experimentally induced crush injury. Reported preclini-
cal observations include accelerated nerve and muscle 
fiber regeneration, increased nerve conduction veloc-
ity, increased levels of neuritic protein neurofilaments, 
increased axon myelin surface area and thickness, and 
increased levels of neuronal cell membrane phospholip-
ids phosphatidylcholine and phosphatidylethanolamine 
following nucleotide administration.19-22 In the clinical 
setting, the combination of UTP and CMP with vitamin 
B
12
 has been investigated in several painful conditions with 
favorable results, among which are diabetic neuropathy, 
acute non-traumatic pain, lumbar pain, cervical pain, and 
traumatic-compressive lesions.10-13, 18
Objectives
The objectives of this study were to assess the safety and 
efficacy of the combination of nucleotides (UTP and CMP) 
and vitamin B
12
 in patients presenting with neuralgia arising 
from neural compression associated with degenerative ortho-
pedic alterations and trauma, and to compare these effects 




This was a randomized, double-blind, comparative, con-
trolled trial performed at UNIFESO Medical School 
 facilities and hospital. The study was registered with the Bra-
zilian National Database GGMED/GESF-ANVISA under 
the following numbers: NOTIFICAÇÃO EM PESQUISA 
CLÍNICA Nº 61/2014 Expediente do CE: 0331070141. 
After study approval by the UNIFESO ethical committee 
(approval no 509.682) and written informed consent of all 
participants, subjects meeting inclusion criteria were ran-
domized to a 30-day oral treatment period. Inclusion criteria 
included patients of both genders, ≥18 years of age, with 
a clinical presentation of degenerative orthopedic altera-
tion with neural compression. Female patients performed a 
urine pregnancy test prior to inclusion and were required to 
maintain adequate birth control throughout the study period. 
Exclusion criteria included need for surgical treatment and 
need for other analgesics. 
Enrolled subjects were randomized by order of arrival to 
the study center into two treatment groups: Group A received 
the combination of nucleotides and vitamin B
12,
 while sub-
jects in Group B received vitamin B
12
 monotherapy. The study 
drug and treatment regimen was two capsules, three times 
per day for Group A. Each capsule contained: CMP 2.5 mg; 
UTP 1.5 mg; and hydroxocobalamin 1.0 mg. Study treatment 
regimen for subjects in Group B was two capsules, three times 
per day, each capsule contained hydroxocobalamin 1.0 mg. 
There was no visible difference between the study drugs, in 
accordance with blinding procedures for double-blind trials. 
Subjects were instructed to swallow the capsules whole at 
breakfast, lunch, and dinner. 
The study hypothesis was that the combination of nucleo-
tides and vitamin B
12
 would show superior efficacy in rela-
tion to B
12
 monotherapy. The study protocol outlined three 
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Compressive neuralgia treatment alternative
randomization, and study drug distribution; visit two took 
place after 15 days of treatment; and visit three occurred at 
the end of the 30-day treatment period. At each of these study 
visits, subjects underwent a series of efficacy and tolerability 
assessments. 
Efficacy assessments included a 100 visual analog pain 
scale (VAS), and the Patient Functionality Questionnaire 
(PFQ), a 12-item yes or no questionnaire about management 
of daily needs. The assessment included sleep quality, need 
to rest, ability to get up, standing and climbing stairs, wash-
ing, drying, and dressing, picking up things from the floor, 
changing posture, carrying weight, and need for assistance 
from other people. At each assessment, the patient and the 
investigating physician also evaluated the patient’s overall 
condition on a scale of 1-10 points.  Safety assessments 
took into account vital signs at each assessment and occur-
rence, severity, and duration of any adverse effects, including 
changes in laboratory tests. 
The primary study endpoint was the percentage of 
subjects presenting VAS ≤20 mm at end of study treatment 
period. Secondary study endpoints included the percentage 
of subjects presenting improvement ≥5 points on the PFQ; 
percentage of subjects presenting pain reduction (reduction 
in VAS scores at study end in relation to pretreatment); and 
number of subjects presenting adverse events. 
Study sample size took into account the results of a previ-
ous study,10 evaluating 80 subjects (40 per treatment group), 
in which mean VAS scores at end of treatment were 21.11 in 
the combination group versus 41.75 in the B
12
 monotherapy 
group. Thus, a study sample size of 400 was determined, 
taking into account the mean between group difference of 
20.6mm and standard deviation of 10.3mm, from the previ-
ous study, with a standard error of 1.03. The 95% confidence 
interval was 18.58–22.62, with a power of 1.0 and a two-
tailed alpha of 0.05. Data were statistically analyzed using 
the software GraphPad Prism 5.0. Overall clinical efficacy 
and tolerability were analyzed via comparison of the results 
of each assessment in relation to pretreatment values, within 
and between treatment groups. For categorical variables, we 
used the χ2 or Fisher’s test, while continuous variables were 
analyzed using the repeated measures ANOVA or Student’s 
t-test. 
Results
A total of 400 subjects were randomized to treatment, with 
200 subjects per treatment group. Figure 1 shows the flow 
of subjects through the trial. No significant between-group 
differences were noted at pretreatment in the demographic 
data and pretreatment characteristics of the study population, 
as summarized in Table 1. 
The safety measures monitored during the study are sum-
marized in Table 2. Pretreatment safety measures did not vary 
significantly between Groups A and B: weight (p=0.148), 
body mass index (BMI) (p=0.532), blood pressure (p=1.0 
for systolic blood pressure and p=0.849 for diastolic blood 
pressure), and heart rate (p=0.413). Throughout the treatment 
period within the treatment groups, with the exception of 
systolic blood pressure in both groups and diastolic blood 
pressure in Group B, there was no statistically significant 
change in weight (Group A, p=0.855; Group B, p =0.0603), 
BMI (Group A, p =0.6; Group B, p =0.257), blood pressure 
(Group A, p = 0.0013 for systolic blood pressure and p=0.133 
for diastolic blood pressure; Group B, p =0.0046 for systolic 
blood pressure and p=0.0032 for diastolic blood pressure), 
and pulse (Group A, p=0.541; Group B, p=0.337). 
Pretreatment PFQ scores were significantly lower among 
patients in Group B (median for Group A, 9.0; median for 
Group B, 8.0; p=0.0036). Median PFQ scores were 5.0 at visit 
two in both treatment groups and 0.0 at visit three in both 
treatment groups. Both groups showed statistically significant 
improvement at the end of the study in relation to pretreat-
ment PFQ scores (p<0.0001 for both treatment groups). 
In relation to the secondary study endpoint, there was no 
between-group difference in the percentage of subjects 
presenting improvement ≥5 points on the PFQ (p=0.135).
Pretreatment patient overall assessment scores were 
homogenous between treatment groups (p=0.29). At visits 
two and three, the scores of this assessment improved within 
each treatment group, but Group A patients showed a greater 
improvement in scores at both visit two (p=0.014) and visit 
three (p=0.0024) in comparison to Group B scores (Figure 2). 
Physician overall assessment scores were also homogenous 
between treatment groups at pretreatment (p=0.717), but 
at visits two and three scores were significantly lower in 
Group A as compared to Group B (p=0.0029 for visit two 
and p=0.006 for visit three) (Figure 3). 
At pretreatment, mean VAS scores among the patients in 
Group A was 51.26mm (±12.38) while in Group B mean pre-
treatment VAS score was 51.06 (±11.72) (p=0.87). Visit two 
VAS scores for Group A and Group B were 29.86 mm (±12.94) 
and 33.88 mm (±11.86) (p=0.0014); At visit three, mean 
Group A VAS scores were 16.06 mm (±12.03) and 20.40 mm 
(±11.42) for Group B (p=0.0003). The percentage of subjects 
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Assessed for eligibility (n=741)
Excluded (n=341)
Not meeting inclusion criteria (n=341)
Refused to participate (n=0)
Other reasons (n=0)
Allocated to Group A (n=200)















Excluded from analysis (n=0)
Allocated to Group B (n=200)








Lost to follow-up (n=1)
Noncompliance  (n=1)
Treatment failure (n=4)
Laboratory alteration (n=1) 
Analyzed (n=191)
Excluded from analysis (n=0)
Figure 1 Flowchart of subjects through the study
visit three was significantly higher in Group A as compared to 
Group B (p=0.0425). Within the treatment groups, VAS score 
reduction was statistically significant for both Group A and 
Group B (p<0.0001 for both groups) (Figure 4). 
Adverse events were recorded in both treatment groups, 
though for the most part these were not serious and were 
transient. Table 3 summarizes the adverse events determined 
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Compressive neuralgia treatment alternative
There was no between-group difference in the percentage 
of subjects presenting adverse events during the treatment 
period (p=0.6009).
Discussion
We report the results of a clinical trial using the combination 
of uridine, cytidine, and vitamin B
12
 in the treatment of neural-
gias caused by degenerative orthopedic alterations with neural 
compression. This combination is commercially available in 
Brazil under the brand name Etna®. The  combination of the 
nucleotides with vitamin B
12
 yielded a more significant pain 
Table 1 Pretreatment and demographic data
Variable Results 




 Male 98 114 
 Female 102 86 
Age (years) 43.74 (±9.73) 44.12 (±10.22) p=0.133
Height (cm) 166.91 (±9.23) 168.49 (±8.86) p=0.0824
Ethnicity p=0.314
 Asian 2 0 
 Black 71 83 
 Caucasian 90 86 
 Mulatto 37 31 
Pain location p=0.5112
 Back pain 125 127 
 Hip pain 45 37 




 Good 72 61 
 Moderate 87 99 
 Poor 41 40 
Alcohol consumption p=0.57
 None 63 72 
 ≤2 drinks/day 82 73 
 >2 drinks/day 55 55 
Cigarette smoking p=0.102
 Non-smoker 91 78 
 <10 cigarettes/day 54 47 
 ≥10 cigarettes/day 55 75 
Manual labor p=0.309
 Light 57 68 
 Moderate 69 56 
 Heavy 74 76 
Physical exercise p=0.415
  Regular (at least  
1×/week) 
49 41 
 Irregular 81 77 
 None 70 82 
Notes: Data are n, or mean (±standard deviation). Group A: subjects treated with 
uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
Table 2 Safety assessments
Parameters Results 
Group A Group B 
Weight (kg)
Pretreatment 72.27 (±12.29) 74.05 (±12.27)
Visit two 72.35 (±12.28 73.87 (±12.29)
Visit three 72.42 (±12.31) 74.04 (±12.39)
BMI
Pretreatment 25.80 (±3.03) 25.99 (±3.05)
Visit two 25.80 (±3.013) 25.96 (±3.099)
Visit three 25.82 (±3.009) 26.02 (±3.121)
Systolic blood pressure  
(mmHg)
Pretreatment 123.7 (±8.541) 123.7 (±7.285)
Visit two 122.4 (±7.376) 122.7 (±8.124)
Visit three 122.4 (±7.813) 123.0 (±7.644)
Diastolic blood presssure  
(mmHg)
Pretreatment 80.29 (±7.42) 80.14 (±8.269)
Visit two 79.67 (±7.755) 79.43 (±8.655)
Visit three 80.04 (±7.576) 79.38 (±8.672)
Pulse (bpm)
Pretreatment 68.54 (±4.644) 68.92 (±4.503)
Visit two 68.17 (±5.165) 68.47 (±5.647)
Visit three 68.30 (±4.789) 68.57 (±4.648)
Notes: Data are n, or mean (±standard deviation). Group A: subjects treated with 
uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.














Pretreatment Group A Pretreatment Group B Visit two Group A
Visit three Group BVisit two Group B Visit three Group A
2 3 4 5 6 7 8 9 10
Figure 2 Patient overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment 
groups A and B at each study visit.
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reduction as measured by the VAS. Assessments performed 
by both the patients and the investigating physician had higher 
scores after 15 and 30 days of treatment among subjects treated 
with the combination. Treatment with the combination and with 
the control of vitamin B
12
 monotherapy resulted in significant 
improvement in patient functionality throughout the treatment 
period, as measured by the patient functionality questionnaire. 
The findings of this study are in agreement with those 
previously described in the literature. A previous study 
performed by Goldberg et al (2009) assessed the use of this 
combination in the treatment of back pain and hip pain, 
reporting significant reduction in pain assessments as well 
as functionality.10 As with the study of Goldberg and also 
another recent study in alcoholic polyneuropathy in which the 
authors compared the use of the combination of UTP + CMP 
+ vitamin B
12
 with the use of vitamin B
12
 monotherapy,17 there 
was a significant improvement over the treatment period in 
pain manifestations as compared to the monotherapy group, 
although the patients within the monotherapy group also dis-
played significant improvement throughout the treatment as 
compared to pretreatment status. This finding and that of our 
study highlights the importance the vitamin B
12
 component 
in the treatment of these painful conditions.
A limitation of this study was the inclusion of three 








Pretreatment Group A Pretreatment Group B Visit two Group A
Visit three Group BVisit two Group B Visit three Group A








Figure 3 Physician overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment 
groups A and B at each study visit.
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
VAS




































Figure 4 Visual analog scale scores for pain, for treatment groups A and B. 
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: 
subjects treated with vitamin B12 alone.
Abbreviations: PT, pretreatment; VAS, visual analog scale; V2, visit two (after 15 
days of treatment); V3, visit three (after 30 days of treatment). 
Table 3 Adverse events considered to be associated with study 
drug administration




Abdominal colic Mild 1 
Abdominal discomfort Moderate 1 
Abdominal distension Moderate 2 
Abdominal distension Mild 1 
Abdominal disturbance Moderate 1 
Feeling of bloating Moderate 1 
Flatulence Moderate 1 
Increased appetite Mild 1 
Nausea Moderate 1 
Nausea Mild 3 
Group B 
Abdominal discomfort Mild 1 
Abdominal distension Moderate 1 
Abdominal distension Mild 1 
Constipation Moderate 1 
Constipation Mild 1 
Elevated uric acid Mild 2 
Epigastralgia Mild 2 
Epigastralgia Moderate 1 
Flatulence Mild 1 
Nausea Moderate 1 
Nausea Mild 1 
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: 
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Compressive neuralgia treatment alternative
syndrome which ultimately reduced the number of subjects 
in each pain subcategory. Future studies should focus on a 
single pain location in order achieve more specific results. 
Nevertheless, we believe the results of this study are in con-
cordance with findings in the literature and serve to contribute 
to the growing body of evidence indicating the therapeutic 
value of the combination of UTP,CMP and vitamin B12 for 
the treatment of peripheral neuropathies. It is also important 
to point out that unlike vitamin B
12
 (which has been confirmed 
to exhibit antinociceptive effects in both animal and human 
studies) the nucleotides do not have any direct role in anti-
inflammation or analgesia and thus the symptomatic improve-
ments observed in our study and in previous studies are 
suggestive of structural neuroregeneration by the nucleotides 
as a mechanism of action.10, 11, 14, 15 Indeed, previous studies 
on animal models give credence to this notion, with previ-
ous observations of the nucleotides playing a positive role in 
axon and myelin sheaths of nerve and muscle fibers during 
regeneration following experimentally-induced damage, in 
addition to improved nerve fiber conduction velocity.19-21 
A combination of uridine, folic acid, and vitamin B
12
 was 
recently reported to be effective in the treatment of carpal 
tunnel syndrome. Although in a small scale exploratory 
trial of 48 subjects, authors reported reduced pain scores 
and improvement in symptom intensity following 60 days 
of treatment with the combination therapy.23 An important 
limiting factor in our study with regards to carpal tunnel 
syndrome is the relatively small sample size in relation to 
the total patient population, as mentioned in the preceding 
paragraph. However, these findings together with the results 
of our study warrant further investigation into the use of the 
nucleotides and vitamin B
12
 in the treatment of this very 
common ailment. 
Clinical trials of painful conditions attributable to neuro-
pathic pain (pain following neurological surgical procedures, 
neural compression-induced neuralgias, chronic neuropathic 
lumbar pain, peripheral neuropathies, and pain and paresthesia 
related to B
12
 deficiency anemia) have consistently yielded 
encouraging results with use of the combination of uridine, 
cytidine, and vitamin B
12
, and further studies may reveal 
additional indications where this combination or others like 
it may be of use, while also expanding our understanding of 
the interaction between the nucleotides and vitamin B
12
 in 
painful conditions.9-21 For instance, the combination of uridine, 
folic acid, and vitamin B
12
 was also reported to be effective in 
neuropathic pain of peripheral neuropathies, with a reduction 
in pain intensity and also allowing for reduction in concomi-
tant medication use.23,24 These types of study are important 
to explore new alternatives for  addressing  neuropathic pain 
– with the aim of providing treatment options that reduce 
pain, decreased need for other drugs with more unwanted side 
effects, and improve patient care and quality of life. 
Conclusion
The results of this study showed a more expressive improve-
ment in efficacy evaluations among subjects treated with the 
combination of nucleotides + vitamin B
12
, with a statistically 
significant superiority of the combination in pain reduction 
(evidenced by VAS scores). There were adverse events in 
both treatment groups, but these were transitory and no 
severe adverse event was recorded during the study period. 
Safety parameters were maintained throughout the study in 
both treatment groups. The combination of uridine, cytidine, 
and vitamin B
12
 was safe and effective in the treatment of 
neuralgias arising from neural compression associated with 
degenerative orthopedic alterations and trauma. Consider-
ing these results, a prospective, multi-center randomized 
controlled clinical trial, comparing the activity of vitamin 
B
12
 alone to the activity of vitamin B
12
 in combination with 
nucleotides in pain reduction, is warranted. 
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